Adherence and blood pressure control in patients with primary aldosteronism.
Primary aldosteronism
adherence
antihypertensive treatment
blood pressure
chromatography–mass spectrometry
Journal
Blood pressure
ISSN: 1651-1999
Titre abrégé: Blood Press
Pays: England
ID NLM: 9301454
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
19
4
2022
pubmed:
20
4
2022
medline:
21
4
2022
Statut:
ppublish
Résumé
The aim of our study was to evaluate the adherence to mineralocorticoid receptor (MR) antagonists and other antihypertensive therapy and blood pressure control in conservatively treated patients with primary aldosteronism (PA). Conservatively treated subjects with previously confirmed PA (n-50, 64.5 ± 9 years of age, 24% women) were investigated Good blood pressure control was detected (mean 24 h systolic/diastolic BP 130 ± 12/77 ± 9 mmHg). The average number of antihypertensive drugs was 3.9 ± 1.5. All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 ± 20 mg) and in the remaining 56% of subjects eplerenone was administered (average daily dose 80 ± 30 mg) due to spironolactone side effects. Assessment of antihypertensive drug concentrations revealed full adherence in 80% of all subjects, partial nonadherence was noted in the remaining 20% of subjects. MR antagonist levels were detected in almost all subjects (49 out of 50). Good blood pressure control and adherence to therapy were detected in conservatively treated patients with PA. Eplerenone had to be used quite often as male subjects did not tolerate dose escalation due to spironolactone side effects.
Identifiants
pubmed: 35438025
doi: 10.1080/08037051.2022.2061416
doi:
Substances chimiques
Antihypertensive Agents
0
Mineralocorticoid Receptor Antagonists
0
Spironolactone
27O7W4T232
Eplerenone
6995V82D0B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM